# A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT03164057** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 206 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Decitabine
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Etoposide
- **COMBINATION_PRODUCT:** ITMHA
- **DRUG:** Idarubicin
- **DRUG:** Fludarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Erwinia asparaginase
- **DRUG:** Sorafenib
- **DRUG:** G-CSF
- **DRUG:** Dexrazoxane
- **BIOLOGICAL:** Stem Cell Transplant
- **DRUG:** Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn

## Key facts

- **NCT ID:** NCT03164057
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-15
- **Primary completion:** 2025-09-20
- **Final completion:** 2027-06
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164057, "A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03164057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*